LivaNova (NASDAQ:LIVN) Stock Rating Lowered by BidaskClub
Several other brokerages have also weighed in on LIVN. Piper Jaffray Companies set a $90.00 price objective on LivaNova and gave the company a “buy” rating in a report on Friday, September 6th. ValuEngine raised LivaNova from a “hold” rating to a “buy” rating in a report on Thursday, November 7th. Berenberg Bank reissued a “buy” rating and set a $114.00 price objective on shares of LivaNova in a report on Monday, September 9th. Stifel Nicolaus increased their price objective on LivaNova from $80.00 to $90.00 and gave the company a “buy” rating in a report on Monday, November 25th. Finally, Needham & Company LLC reissued a “buy” rating and set a $88.00 price objective on shares of LivaNova in a report on Wednesday, November 20th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. LivaNova has a consensus rating of “Buy” and an average target price of $96.00.
Shares of LIVN stock opened at $78.80 on Thursday. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.17 and a quick ratio of 0.81. LivaNova has a fifty-two week low of $64.80 and a fifty-two week high of $102.43. The stock’s 50-day moving average is $77.84 and its two-hundred day moving average is $75.84. The firm has a market cap of $3.81 billion, a P/E ratio of 24.86, a PEG ratio of 3.80 and a beta of 0.59.
In other news, CEO Damien Mcdonald sold 1,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $73.82, for a total transaction of $73,820.00. Also, Director Daniel Jeffrey Moore sold 3,000 shares of the stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $80.00, for a total value of $240,000.00. Following the transaction, the director now directly owns 28,352 shares in the company, valued at approximately $2,268,160. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,500 shares of company stock worth $598,070. 0.41% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in LivaNova by 18.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 2,395,068 shares of the company’s stock valued at $172,349,000 after purchasing an additional 378,564 shares during the period. Invesco Ltd. boosted its stake in LivaNova by 376.8% during the 2nd quarter. Invesco Ltd. now owns 2,299,007 shares of the company’s stock valued at $165,437,000 after purchasing an additional 1,816,788 shares during the period. UBS Asset Management Americas Inc. boosted its stake in LivaNova by 22.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 1,390,299 shares of the company’s stock valued at $100,046,000 after purchasing an additional 259,369 shares during the period. Wells Fargo & Company MN boosted its stake in LivaNova by 11.5% during the 2nd quarter. Wells Fargo & Company MN now owns 1,322,072 shares of the company’s stock valued at $95,136,000 after purchasing an additional 136,777 shares during the period. Finally, Northern Trust Corp boosted its stake in LivaNova by 0.6% during the 2nd quarter. Northern Trust Corp now owns 778,763 shares of the company’s stock valued at $56,040,000 after purchasing an additional 4,317 shares during the period. 87.80% of the stock is currently owned by institutional investors and hedge funds.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Recommended Story: What is an overbought condition?
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.